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We previously reported that early arthritis (EA) patients with low vasoactive intestinal peptide (VIP) 
serum levels demonstrate a worse clinical disease course. In this study, we analysed whether variants in 
the VIP gene correlated with its serum levels and clinical EA parameters. The VIP gene was sequenced 
in patients with extremely high/low VIP levels, measured by enzyme immunoassay. Sixteen single 
nucleotide polymorphisms (SNPs) were differentially distributed between both groups, which were 
subsequently genotyped in two patients’ sets. We observed that patients with rs688136 CC genotype 
showed higher VIP levels in both discovery (n = 91; p = 0.033) and validation populations (n = 131; 
p = 0.007). This effect was attenuated by the presence of minor alleles rs35643203 and rs12201140, 
which showed a clear trend towards low VIP level association (p = 0.118 and p = 0.049, respectively). 
Functional studies with miR-205-5p, which has a target site in the 3′ UTR close to rs688136, 
revealed a miRNA-mediated regulatory mechanism explaining the higher VIP gene expression in 
homozygous patients. Moreover, patients with an rs688136 CC genotype and no minor alleles of the 
other polymorphisms required less treatment (p = 0.009). We concluded that the identification of 
polymorphisms associated with VIP serum levels would complement the clinical assessment of the 
disease severity in rheumatoid arthritis patients.
Rheumatoid arthritis (RA) is a chronic, polygenic immune-mediated inflammatory disease that leads to signifi-
cant joint damage, pain, and disability if not treated1. The pathogenesis of RA is not completely understood, but 
genetic factors account for approximately 60% of disease susceptibility2, as well as interactions with environmen-
tal factors, such as tobacco use and diet, which trigger the development of the disease3–5.
RA affects 0.5–1% of the adult population worldwide, resulting in significant social costs in terms of disability, 
increased comorbidities, impaired quality of life and decreased life expectancy6,7.
According to the “window of opportunity” concept, aggressive disease-modifying anti-rheumatic drug 
(DMARD) treatment at the earliest stages of the disease can prevent irreversible structural damage and 
even increase the possibility of achieving DMARD-free remission8,9. Heterogeneity in the disease course is 
well-established in RA, therefore treating all patients with aggressive DMARD schedules could be unacceptable 
in certain cases in which the risk of adverse events could outweigh the benefits. Available biomarkers of severity, 
such as rheumatoid factor or anti-citrullinated peptide antibodies (ACPAs), do not accurately identify all patients 
requiring more intensive treatment10. Thus, the ongoing search for new prognostic biomarkers represents an 
important challenge in the management of RA in order to establish an intensive and appropriate treatment at 
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the beginning of the disease, with the purpose of change the disease course in patients predicted to have a worse 
prognosis. Vasoactive intestinal peptide (VIP) is a homeostatic and immunoregulatory peptide involved in the 
control of both innate and adaptive immune response. Exogenous administration of VIP exerts therapeutic effects 
in models of autoimmune/inflammatory disorders, including inflammatory bowel disease11, experimental auto-
immune encephalomyelitis12, Sjögren’s syndrome13, and autoimmune diabetes14, as well as in a murine model of 
collagen-induced arthritis15. In humans, VIP exerts its protective effects by inhibiting the macrophage proinflam-
matory polarization profile16, changing the Th1/Th2 balance in CD4 T cell differentiation in favor of Th2 cells17, 
promoting the acquisition of a Th17 non-pathogenic profile18 and inducing regulatory T cells18–20.
The immunoregulatory function of endogenous VIP is supported by the fact that several inflammatory/auto-
immune diseases are associated with reduced levels of VIP in serum21. In this regard, we have recently reported 
that patients with Early Arthritis (EA) and early Spondyloarthritis (SpA) who displayed low VIP serum levels at 
disease onset appeared to develop a greater burden of disease22,23. However, using VIP serum levels as a viable 
biomarker in daily clinical practice presents methodological problems, such as the inter-assay variability of the 
enzyme immunoassay (EIA) method22. Therefore, in this study, we investigated whether variations in the DNA 
sequence of the VIP gene were associated with VIP expression and whether they could reproduce the prognostic 
value previously described for VIP serum levels. Furthermore, we propose a possible functional mechanism to 
explain the contribution of one of these genetic variants in the VIP gene to its serum levels.
Results
Patient characteristics and sequencing of the VIP gene. The characteristics of the EA patient sub-
populations included in the present study (91 patients for the discovery phase and 131 for the validation phase) 
are shown in Table 1.
We selected 20 patients from the discovery population, which displayed extremely divergent baseline serum 
VIP levels, for the sequencing screening of the VIP gene. The characteristics of this subset of patients are shown 
in Supplementary Table 1. Sequences and lengths of the primers used for sequencing experiments are detailed in 
Supplementary Table 2.
EA patients with high or low serum VIP levels show different genetic variations in the VIP gene. 
High-quality sequencing data were obtained for 20 patients comprising the screening set. After comparing their 
VIP sequences with the consensus sequence24, we found 120 variants, most of which were distributed randomly 
between the 2 subsets. Among these variants, we observed 16 SNPs differentially distributed in both groups 
(Fig. 1a and Supplementary Table 3). Next, we genotyped these 16 variants in two different sets of EA patients 
by sequencing or using SNP TaqMan probes, as detailed in the Methods section. Genotyping of PEARL samples 
showed that the following five SNPs had a minor allele frequency (MAF) of <5% in our population and were 
therefore excluded from statistical analysis: rs60946248, rs140023105, rs185451870, rs74760293, and rs149081483 
(number of cases and MAF shown in Supplementary Table 3).
Next, we studied whether the rest of the SNPs were in linkage disequilibrium (LD). The R2 value was >0.9 for 
rs12213214, rs3799142, rs7764067 and rs12201173. We chose rs12213214 as the tagSNP for this group since that 
polymorphism is located in the promoter region. In addition, rs3823082 showed an R2 = 0.614 with rs12213214. 
As shown in Fig. 1b, applying the Gabriel method25, we observed that these five SNPs formed a haplotype block. 
On the other hand, rs35643203 and rs71575932 were in LD (R2 = 0.88), and we chose rs35643203 as the tagSNP. 
The remaining polymorphisms were studied separately since they were not in LD with any other polymorphism.
Genetic variants in the VIP gene influence serum levels of VIP in EA patients in the discovery 
phase. Next, to assess the relationship between VIP levels and selected polymorphisms on the VIP gene, 
we performed a preliminary bivariate analysis. As shown in Supplementary Table 4, in the discovery popula-
tion, patients with one minor allele of rs35643203 had significantly lower serum VIP levels than homozygous 
Discovery population (n = 91) Validation population (n = 131) p Meta-analysis (n = 222)
Female gender (%) 64 (70) 108 (82) 0.08 172 (77)
Age 54 [44–66] 54 [44–67] 0.88 54 [44–66]
Diagnosis RA/UA (%) 69 (76)/22 (24) 92 (70)/39 (30) 0.45 161 (73)/61 (27)
Positive RF (%) 38 (42) 73 (56) 0.04 111 (50)
Positive ACPA (%) 42 (46) 70 (53) 0.32 112 (50)
Ever smoker (%) 47 (52) 68 (52) 0.89 115 (48)
DAS28 (0–10) 4.8 [3.5–5.9] 4.1 [3.4–5.5] 0.16 4.5 [3.4–5.7]
HUPI 7.5 [6–10] 6.5 [4.5–10] 0.09 7 [5–10]
HAQ 1 [0.625–1.625] 0.875 [0.375–1.625] 0.29 1 [0.5–1.625]
VIP (pg/ml) 456 [383–501] 529 [460–595] 0.63 453 [384–519]
Table 1. Baseline characteristics of PEARL subpopulations. Data are shown as the median and the interquartile 
range or as the percentage. RA: rheumatoid arthritis; UA: undifferentiated arthritis; RF: rheumatoid factor; 
ACPA: anti-citrullinated peptide antibodies; DAS28: 28-joint count Disease Activity Score; HUPI: Hospital 
Universitario La Princesa Index for disease activity; HAQ: health assessment questionnaire; VIP: vasoactive 
intestinal peptide. Statistical significance was established by t test or Mann-Whitney test for a p-value < 0.05.
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patients for the major allele. In addition, patients carrying one minor allele of rs3823082 and rs7755568 showed a 
non-significant trend towards lower VIP levels than those with two copies of the major allele. On the other hand, 
the only SNP that appeared to be related with increased VIP levels was rs688136. For this reason, we decided to 
include it in the multivariable analysis.
We have previously described that there were no significant differences in VIP serum levels between healthy 
donors and patients with arthritis. However, more heterogeneous ranges of VIP serum levels were observed 
in patients with either RA or UA (Undifferentiated Arthritis)22. In addition, age at disease onset and use of 
TNF-blocking agents has been reported to influence VIP levels22,23. Therefore, we decided to perform a multi-
variable analysis to further elucidate the precise contribution of these SNPs to the evolution of serum VIP levels 
during the course of arthritis.
In this context, and according to what we have described before, we observed that in patients who were treated 
with TNF blockers, VIP serum levels were significantly increased (Supplementary Table 5; Model 1). In addition, 
we confirmed that older patients tended to show higher VIP levels (Supplementary Table 5; Model 1). After 
adjusting for these confounders, we found that patients with the CC genotype of the rs688136 allele had signif-
icantly higher levels of serum VIP (Supplementary Table 5; Model 1; p = 0.033). In contrast, having one minor 
allele of rs35643203 or of rs12201140 were associated with lower serum VIP levels (Supplementary Table 5; Model 
1; (p = 0.05) and (p = 0.068), respectively).
Validation phase and meta-analysis. To confirm the association between SNPs of the VIP gene and VIP 
serum levels observed in the discovery population, we replicated the analyses in a new set of 131 patients. The 
Figure 1. Sequencing of VIP gene and linkage disequilibrium (LD) Plot. (a) Structural diagram of VIP gene 
comprising the promoter region, 7 exons and 6 introns. The upper diagram shows mRNA transcription and 
the bottom diagram represents the 29 overlapping amplicons used for sequencing, as well as the SNPs found. 
SNPs chosen for further study are highlighted in bold. (b) Plot showing LD patterns among genotyped SNPs. 
LD is measured as r2 and shown (×100) in the diamond at the intersection of diagonals from each SNP. r2 = 0 
shown in white, 0 < r2 < 1 shown in grey and r2 = 1 shown in black. Top analysis track represents chromosomal 
location. Bold black line outlines one haplotype block designating markers in high LD.
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association between CC genotype for rs688136 with higher VIP levels was confirmed in both bivariate analysis 
(p = 0.002) (Supplementary Table 4) and multivariate analysis (p = 0.007) (Supplementary Table 5 model 1).
In a further step, a meta-analysis of both populations (n = 222) performed for rs688136 showed that the 
association between CC genotype and high VIP levels remained statistically significant, both in the bivariate 
(p = 0.008) and multivariate analysis (p = 0.004) (Fig. 2a, Table 2 model 1 and Supplementary Table 5). By means 
of the multivariate analysis, we also confirmed a significant association between serum VIP levels and rs12201140 
in the meta-analysis (p = 0.049) (Fig. 2b and Table 2 model 1) and a non-significant trend for the rs35643203 
(p = 0.118) (Fig. 2c and Table 2 model 1).
Interactions between polymorphisms in the VIP gene could modify VIP serum levels. Since we 
observed a marked heterogeneity in VIP serum levels among genotypes of each SNP, we investigated if interac-
tions between the genetic variants of the VIP gene could explain this variability. Thus, we created an Interaction 
Score as a categorical variable that let us cluster the patients into 4 groups according to the different genotype 
combinations of the polymorphisms rs688136, rs35643203 and rs12201140. Clusters were established as follows:
 a) Patients carrying the CT or TT genotype of rs688136 and no rs35643203 or rs12201140 minor alleles.
 b) Patients carrying the CT or TT genotype of rs688136 and at least 1 minor allele of either rs35643203 or 
rs12201140.
 c) Patients carrying the CC genotype of rs688136 and no rs35643203 or rs12201140 minor alleles.
 d) Patients carrying the CC genotype of rs688136 and at least 1 minor allele of either rs35643203 or 
rs12201140.
We consider the population of reference to be the one that showed the minimum variations with respect to the 
consensus sequence in relation to the genetic variants of the study, that is, the population of patients with CT or 
TT genotypes of rs688136 and no minor alleles of the other polymorphisms. As shown in Fig. 2d, patients with a 
CC genotype of rs688136 and no minor alleles of the other SNPs showed the highest VIP serum levels (p = 0.006). 
The group with the lowest levels was the one who had at least one major allele of rs688136 and at least one minor 
allele of the other SNPs (Fig. 2d, Table 2 model 2). Interestingly, those patients with the CC genotype of rs688136 
(associated with high VIP levels) and at least,one minor allele of rs35643203 or rs12201140 (associated with low 
VIP levels) displayed similar VIP levels to the reference population (Fig. 2d and Table 2 model 2).
Figure 2. Serum VIP levels in EA patients according to different genotypes. Serum VIP levels according to 
the genotype of the: (a) rs688136; (b) rs12201140; (c) rs35643203. (d) Interaction Score for different genotype 
combinations of VIP gene polymorphisms associated with VIP serum levels. In all panels data from the meta-
analysis (n = 222) are presented as the interquartile range (p75 upper edge of the box, p25 bottom edge, and 
p50 midline), p90 and p10 (lines below and above the box) of the serum VIP levels. Statistical significance for a 
p-value < 0.05 was established by means of a multivariate analysis adjusted by age of onset and TNFα blockers 
and nested by patient and visit. Dots represent outliers. ns: non-significant.
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Minor allele of rs688136 interferes with the downregulation of VIP expression induced by miR-
205-5p. Next, we tried to elucidate the mechanism involved in the differences of VIP serum levels associated 
with the presence of the T/C allele of the rs688136. Since this polymorphism is located at the 3′UTR, which plays 
a role in the regulation of the expression of most mRNA, the PsiCheck-2 vector was constructed as explained in 
the Methods section. A Dual Luciferase Assay was performed in order to determine whether the mere presence 
of the T allele was associated with a minor luciferase activity and, thus, to a reduced gene expression. As shown 
in Fig. 3a, we did not observe statistically significant differences between the luciferase activities of both vector 
constructs, but there was a trend towards a decreased expression in the presence of the T allele.
As miRNA binding sites have been described as one of the regulatory mechanisms in the 3′UTR, we searched 
in Target Scan (www.targetscan.org) and miRBase (www.mirbase.org) for miRNAs with predicted binding sites 
close to the SNP rs688136 and identified the has-miR-205-5p (Fig. 3b). Thus, we co-transfected Jurkat cells with 
the PsiCheck-2 vectors (T-insert or C-insert), and this miRNA. Another co-transfection with the mimic cel-miR-
39-3p was performed as a control miRNA experiment. The result of the Dual Luciferase Assay showed that in 
the presence of miR205-5p, cells co-transfected with the T-insert vector displayed a significant decreased gene 
expression in terms of lower luciferase activity, whereas the vector with the C allele of rs688136 was resistant to 
the regulatory effect of miR-205-5p (Fig. 3c; p = 0.049).
Combinations of genetic variants of VIP gene are associated with treatment requirements in 
EA patients. Finally, as we have previously reported that low serum VIP levels are associated with poor out-
comes in EA patients22, we investigated whether genetic variants of VIP associated with its protein levels were also 
associated with disease severity. No relevant differences in disease activity were observed among patients with dif-
ferent genetic variants of VIP (data not shown), likely due to a wide implementation of the treat-to-target strategy 
in our population26. Therefore, we studied the intensity of DMARD treatment as a surrogate variable of disease 
severity. As described previously by our group and others10, female patients and ACPA-positive patients showed a 
trend towards more intense DMARD treatment (Table 3). In contrast, patients older than 65 years old and those 
not fulfilling the RA criteria received less intense treatment (Table 3). Finally, as is well-known, a significant var-
iability in the intensity of DMARD treatment among physicians was observed10,27 (Table 3). Adjusting for these 




pβ coeff ± SE β coeff ± SE
rs688136
 TT Ref. — —
 TC −1 ± 16.1 0.929
 CC 79 ± 27.9 0.004
rs35643203
 CC Ref. — —
 CT −38 ± 24.1 0.118
 TT 16 ± 81.3 0.845
rs12201140
 AA Ref. — —
 AT −35 ± 17.6 0.049
 TT −100 ± 71.3 0.162
Interaction Score
 CT or TT and no other minor alleles — — Ref.
 CT or TT and other minor alleles −37 ± 14.1 0.009
 CC and no other minor alleles 99 ± 36.3 0.006
 CC and other minor alleles 12 ± 27.8 0.669
Onset Age
 <45 Ref. Ref.
 45–65 31 ± 18.4 0.090 31 ± 16.2 0.052
 >65 27 ± 20.3 0.179 33 ± 17.7 0.065
TNF blockers
 No Ref. Ref.
 Yes 73 ± 34.1 0.031 65 ± 30.8 0.036
Table 2. Polymorphisms associated with VIP serum levels during the follow-up of patients with early 
arthritis in a multivariate analysis. The longitudinal analysis was performed with data from consecutive 
visits corresponding to the meta-analysis (n = 222). Included patients had, at least, two visits along the 
follow-up. Signification was established by means of generalized estimating equations nested by patient and 
visit. Multivariable model fitted by a backward-stepwise selection. Model 1 fitted including independent 
polymorphisms and Model 2 including the Interaction Score. Ref.: reference value; β coeff: beta coefficient; SE: 
standard error; TNF: tumour necrosis factor.
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significantly associated with less intensive treatment requirements, whereas carrying the CC genotype plus at least 
one of the minor alleles of the SNPs associated with lower VIP levels (Table 3, p = 0.009; Supplementary Table 6). 
Therefore, similar to our previous description of VIP serum levels22, the genotype associated with high VIP levels 
was also associated with less severe disease and thus with a reduced need for intensive treatment.
Discussion
Studies of genetic variants influencing the risk of developing autoimmune diseases are numerous28. However, 
there are few reports concerning how genetic variability can modulate the severity of autoimmune disorders. This 
latter approach may be particularly useful when designing an optimal treatment for patients with autoimmune 
diseases. In this regard, to our knowledge, this study is the first to demonstrate that several polymorphisms of 
the VIP gene are associated with differences in serum levels in patients with early arthritis. Considering that low 
serum VIP levels have been associated with worse disease courses and greater treatment needs22, the SNPs of VIP 
identified herein and associated with VIP serum levels could be potential indicators of treatment requirements 
and, therefore, disease severity in patients with recent onset.
VIP is an endogenous mediator involved in the maintenance of homeostasis of the endocrine, nervous, and 
immune systems29–31. Administration of exogenous VIP has improved clinical outcomes in several experimental 
inflammatory/autoimmune murine models11–15,32. Moreover, ex vivo assays with synovial fibroblasts (SFs) and 
peripheral blood lymphocytes (PBLs) in RA patients have supported these results. VIP is able to reduce the pro-
duction of inflammatory mediators by SFs via TLR signalling pathways33–35 and modify the functional capacity of 
human lymphocytes by inducing Th2/Treg differentiation36. In light of this collective evidence, it can be hypoth-
esized that low serum VIP levels may lead to inadequate control of the immune system. In this sense, decreased 
levels of VIP have been described in patients with autoimmune diseases, such as multiple sclerosis37 and autoim-
mune thyroiditis, in this case associated with high levels of VIPase autoantibodies38. Moreover, reduced levels of 
VIP are associated with more severe disease in Chagas cardiomyopathy39 and juvenile idiopathic arthritis, with 
clinical evidence of cardiac autonomic neuropathy40. In rheumatic diseases, an association between low VIP levels 
Figure 3. VIP 3′UTR as a target of miRNA miR-205-5p. (a) Transfection with empty PsiCheck2 vector and 
PsiCheck2 vector-3′UTR inserts with T or C allele for the rs688136 respectively. Data are represented as 
the mean ± SEM. n = 10 each group. n.s: non-significant. (b) Bioinformatic prediction of hsa-miR-205-5p 
recognition elements on human VIP 3′UTR. Analyses performed with the TargetScanHuman algorithm. 
Letter U highlighted in bold corresponds to rs688136 position. Dotted box indicates pairing region. (c) Co-
transfection with PsiCheck2 vector-3′UTR inserts with T or C allele and mimic miRNAs miR-205-5p and miR-
39-3p (control). Data are represented as the mean ± SEM. n = 8 each group. RLU: relative luminescence unit. 
Statistical significance in panels a and c was established using Mann-Whitney test for a p-value < 0.05. Each 
experiment was made in duplicate.
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in serum and worse outcomes in patients with RA and SpA22,23 and joint damage in osteoarthritis patients has 
been reported41,42.
Our results show that variations of the VIP gene affect its serum levels in EA patients. Specifically, we reported 
that rs35643203 and rs12201140, which are located in intron regions 1 and 4, respectively (Fig. 1a), are associated 
with a lower concentration of VIP in serum. The mechanisms through which those SNPs regulate the expression 
of VIP levels remains unclear, but several SNPs located in intronic regions of genes such as STAT4 and CLEC16A 
have been reported to modify the expression of their mRNA and confer a higher risk of developing RA43,44. It has 
been suggested that the presence of SNPs in intronic regions could affect splicing efficiency by generating a tran-
script that lacks an exon, as reported for the HMGCR gene45,46, or by altering the stability of mRNA, as described 
for the MDR1 gene47. However, the functional significance of the SNPs herein remain to be elucidated.
In contrast, rs688136, located at exon 7 encoding for the 3′UTR region of the mRNA, was associated with 
increased levels of VIP. Since the 3′UTR region can include regulatory sequences, polymorphisms in this area 
could elude regulatory mechanisms, thereby resulting in the modification of VIP expression. One of these mech-
anisms are miRNAs, small endogenous RNA species that primarily target the 3′UTR of mRNA transcripts with 
well-known roles in suppressing translation or inducing degradation of mRNA48,49, consequently modulating 
gene expression. A putative target sequence of miR-205-5p was identified in the VIP 3′UTR near rs688136. Our 
data suggest that the C allelic variant in that SNP is not recognized as efficiently as the T variant by miR-205-5p, 
resulting in increased VIP mRNA expression and in high serum levels of this peptide. There are indeed several 
studies showing how the presence of SNPs in 3′UTR can affect microRNA binding and, thus, its regulatory effects 
on gene expression50–52.
We also contributed to the development of a variable that allowed us to assess the effect of genotype combina-
tions associated with serum VIP levels, the Interaction Score. This variable could potentially correlate with clinical 
outcomes, as we have previously described for serum levels22.
Our study is subject to several limitations. First, and not surprisingly, serum VIP levels cannot be thoroughly 
explained by the presence of the genetic variants described herein. Consequently, other mechanisms must be 
involved in the modulation of serum VIP levels. It is necessary to perform more in-depth studies regarding other 
regulatory mechanisms recently described in RA, such as epigenetic changes. Second, our data set comes from 
a single cohort of patients. However, it should be noted that a replication of our results was performed in two 
independent subpopulations separated in time by more than a year. Moreover, the longitudinal design enabled us 
β coeff ± SE p
Interaction Score
 CT or TT and no other minor alleles Ref.
 CT or TT and other minor alleles −0.14 ± 0.09 0.131
 CC and no other minor alleles −0.62 ± 0.24 0.009
 CC and other minor alleles −0.04 ± 0.19 0.849
Gender
 Male Ref.
 Female 0.15 ± 0.11 0.174
OnsetAge
 <45 Ref.
 45–65 −0.01 ± 0.11 0.958
 >65 −0.11 ± 0.12 0.363
Diagnosis
 RA Ref.
 UA −0.85 ± 0.11 0.000
ACPA
 Negative Ref.
 Positive 0.12 ± 0.10 0.226
Physician
 0 Ref.
 1 0.09 ± 0.18 0.660
 2 0.69 ± 0.14 0.000
 3 −0.41 ± 0.24 0.119
 4 0.06 ± 0.14 0.621
 5 0.31 ± 0.16 0.042
 6 0.32 ± 0.13 0.007
Table 3. Association of genotype combinations of the Interaction Score with the Intensity of Treatment in 
patients with early arthritis. Multivariable analysis. Association analysis performed with data corresponding 
to the meta-analysis (n = 222). Signification was established by means of generalized estimating equations. 
Multivariable model fitted by a backward-stepwise selection. Ref.: reference value; β coeff: beta coefficient; SE: 
standard error.
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to evaluate a considerable number of observations and to better control individual variations. Third, the intensity 
of treatment is a time-dependent variable and is therefore affected by changes in therapeutic strategies and phy-
sicians. To overcome this limitation, all our analyses have been properly adjusted. Additionally, we have a cohort 
in which the performance criteria are homogeneous and a complete, rigorous and exhaustive collection of data 
concerning treatment with DMARDs was accomplished throughout the follow-up.
Conversely, it is well-known that severity assessment in RA patients is highly difficult because it is a compen-
dium of biological, social and psychological factors. Moreover, as arthritis is a multifactorial disease, the classical 
outcomes do not always show the expected efficacy. In this sense, there is an urgent need for treatment as a perti-
nent surrogate marker of disease severity in early arthritis cohorts10.
In summary, we demonstrate an association between serum VIP levels and variants in the VIP gene in EA 
patients. Functional findings suggest the potential involvement of the 3′UTR region in the modulation of VIP 
gene expression, possibly through a miRNA-mediated mechanism. We also describe an interaction between dif-
ferent genetic variants and how certain combinations of genotypes of these variants are associated with a higher 
intensity of treatment in our patients.
Taken together, these results underscore the importance of the detection of VIP genetic variants that enable 
EA patients to be stratified for therapeutic decision making in the ‘window of opportunity’ in EA. In this regard, 
it is likely that our results suggest that ACPA-negative patients carrying the CC genotype of rs688136, without 
minor alleles of rs35643203 or rs12201140, will be candidates for less intensive therapy.
Patients and Methods
Study population. The Princesa Early Arthritis Register Longitudinal (PEARL) study comprised patients 
referred to the Early Arthritis Clinic at the Hospital Universitario La Princesa, Madrid (Spain). To be referred 
to the clinic, patients must have had one or more swollen joints for less than a year. Patients with other specific 
causes of arthritis were excluded. The register’s protocol included five visits during a follow-up period of two years 
(baseline, 6, 12, 24 and 60 months). At each visit, the following data were collected and entered into an electronic 
database: clinical and demographic information; disease duration at the beginning of the follow-up; 28 tender 
and swollen joint counts (TJC and SJC, respectively); global disease activity on a 100 mm visual analogue scale 
assessed both by the patient (GDAP) and the physician (GDAPh); Spanish version of the Health Assessment 
Questionnaire53 and laboratory tests including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) 
and RF levels assessed by nephelometry (positive >20 UI/ ml) and ACPA measured by enzyme immune assay 
(EIA) (Euro-Diagnostica Immunoscan RA; positive >50 UI/ml). A more detailed description of the PEARL pro-
tocol has been published previously54.
For this study, we analysed data from 845 visits belonging to two sets of patients: the discovery phase included 
91 patients enrolled from 2001 to 2009 (349 visits), and the validation phase included 131 patients enrolled from 
2006 to 2013 for (496 visits). The characteristics of these subpopulations of PEARL are shown in Table 1. To 
be included in the study, patients must have had at least 2 years of follow-up, either those who met the 1987 
American College of Rheumatology criteria for RA55 or those considered to have undifferentiated arthritis 
(UA)56, since other specific diagnoses were ruled out. During the 1980s, the term “undifferentiated arthritis” had 
been used to refer to a subpopulation of patients who falls within the spectrum of spondyloarthritis. However, 
during the first decade of this century, UA was more commonly used to refer to a disease that could be considered 
a pre-RA disorder in a considerable proportion of patients56–59.
The Instituto de Investigación Sanitaria La Princesa Research Ethics Committee reviewed and approved the 
protocol of PEARL study (PI-518), and all experiments were performed in accordance with the guidelines and 
regulations of this committee. All patients signed an informed consent form before data were included in the 
register, and biological samples were stored at the local Biobank.
Measurement of serum VIP levels. VIP levels were assessed using a commercially available competi-
tive enzyme immunoassay kit (Phoenix Pharmaceuticals, Karlsruhe, Germany) according to the manufacturer’s 
instructions. To avoid the effects of inter-assay variability of this test in the measurements of each patient, all 
samples corresponding to consecutive visits from the same patient were measured together on the same plate. 
The intra-assay and inter-assay variation coefficients were ≤5% and 15%, respectively, as previously described22.
Genetic studies. Screening DNA sequencing. Genomic DNA was isolated from whole blood using the 
QIAamp DNA Blood Midi Kit (QIAGEN, Hilden, Germany). We selected 20 patients from the discovery popula-
tion who displayed extremely divergent baseline serum VIP levels: 11 of them had serum VIP levels above 601 pg/
ml, and the remaining 9 patients had serum VIP levels below 272 pg/ml [p75 and p25 of a control population, 
respectively22]. The characteristics of these PEARL subpopulations used for the sequencing analysis are shown in 
Supplementary Table 1.
Amplification primers were designed to produce overlapping PCR amplicons to cover the region between 
positions 153071932 and 153080900 (GRCh37.p13) of chromosome 6, which includes the promoter and the 
gene encoding VIP. A total of 58 PCR primer pairs were designed, including the M13 universal primer sequence 
(M13 forward primer sequence, 5′- TGTAAAACGACGGCCAGT-3′; and M13 reverse primer sequence, 5′- 
CAGGAAACAGCTATGACC-3′) to generate 29 amplicons ranging between 393 bp and 788 bp (Fig. 1a and 
Supplementary Table 2). Amplification and cycle sequencing were performed using the BigDye Direct Cycle 
Sequencing Kit, purified using the BigDyeXTerminator Purification Kit and sequencing by 3500xLGenetic 
Analyzer (Applied Biosystems).
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SNP genotyping. Genetic variants selected in the sequencing screening were genotyped in 91 and 131 EA 
patients from PEARL for discovery and validation phases of the study, respectively.
The selected VIP genetic variants rs12213214, rs140023105, rs35643203, rs3799142, rs7764067, rs3823082, 
rs12201173, rs71575932, rs74760293, rs149081483 and rs688136 were genotyped using a pre-designed sin-
gle nucleotide polymorphism (SNP) Genotyping Assays (Part numbers: C__27847302_10, C__27855145_10, 
C___3250637_10, C__27502877_20, C__29430252_10, C__27491244_10, C__32237894_10, C___3250638_10, 
C__25962626_10, C_172567893_10, C___3250639_10, respectively), and rs60946248 and rs185451870 were 
genotyped using a custom SNP Genotyping Assay (Applied Biosystems).
After PCR, the genotype of each sample was determined automatically by measuring allele-specific fluores-
cence on a CFX Touch Real-Time PCR System using the software CFX 3.1 Manager (BioRad). Duplicate samples 
and negative controls were included to verify genotyping accuracy.
The genotype of rs12201030, rs7755568 and rs12201140 was obtained by sequencing amplicon 17, as we 
described above (see amplicon information in Supplementary Table 2). These SNPs are located in a low complex-
ity region with a predominance of A and T bases, making it impossible to obtain specific TaqMan probes.
Generation of VIP 3′UTR luciferase reporter vectors. Neuroblastoma cell line SH-SY5Y was used to 
obtain the VIP 3′ untranslated region (3′UTR), where rs688136 is located. That region was amplified by 
means of PCR using forward and reverse custom primers with the restriction sites for XhoI and NotI 
added (primer forward 5′-TGAAAAAGACCTTTGGAGCAAAGCTGATGACAA-3′, primer reverse, 
5′-CAGGAGAGTAGAACAGATAATCAGTGTGTCTAAATTTG-3′). The PCR amplified 3′UTR 333 bp region 
was cloned into the PsiCheck-2 vector (Promega), in which two different luciferase genes (Firefly and Renilla) 
driven by separate promoters are present. VIP 3′UTR inserts (containing T or C alleles for the rs688136) were 
cloned following the Renilla luciferase gene, which served as the reporter, while the Firefly luciferase gene was 
the internal control.
Transformation was performed in competent bacteria, and transformed colonies were selected by culturing 
in the presence of Ampicillin.
Transfection and luciferase assay. Jurkat cells were grown to a 106/ml confluence in complete media (RPMI, 
10% FBS and 1% Penicillin/Streptomycin). Next, 107cells were electroporated with 20 µg of the PsiCheck-2 vec-
tor constructs (alleles T or C) and, in the co-transfection experiments, 2 pmol of miRCURY LNA microRNA 
Mimics (Exiqon), cel-miR-39-3p (microRNA Mimic control) and has-miR-205-5p. Positive controls containing 
the empty PsiCheck-2 vector were included. After culturing for 24 h at 37 °C, transfected cells were lysed in 500 µl 
1X passive lysis buffer (Promega). Lysates were used in each dual luciferase reaction, conducted according to the 
manufacturer’s instructions (Dual-Luciferase Reporter Assay System, Promega). Triplicate Renilla measurements 
were performed using FLUOstar Omega luminometer (BMG Labtech) and normalized to Firefly measurements. 
Luminescence measurements of has-miR-205-5p co-transfected cells were normalized to the corresponding 
measurements of cel-miR-39-3p co-transfected cells.
Statistical analysis. Normally distributed quantitative variables were expressed as the means ± standard 
deviation, while non-normally distributed variables were expressed as the median and interquartile range (IQR). 
In cases of Normal distribution, bivariate analyses were performed using the t test, while Mann-Whitney or 
Kruskal-Wallis test were used for non-normal variables.
Additional variables were defined to further describe the impact of VIP genetic variants in VIP protein serum 
levels and in the course of arthritis. The variable Interaction Score was developed as a measure of the effect of 
the combination of different genotypes, clustering patients into four categories. On the other hand, the imple-
mentation of the early “treat to target” EULAR recommendation strategy in PEARL patients has yielded similar 
disease activity outcomes, rates of remission and decreases of radiological progression in both ACPA-positive and 
-negative patients. Therefore, we decided to use the intensity of DMARD treatment (IDT)60 as a surrogate variable 
of severity to study whether genetic variants in VIP could be associated with severity in early arthritis patients. 
IDT was assessed as the number of days of treatment with each DMARD during follow-up adjusted for weighted 
coefficients, as described previously54.
Serum VIP levels showed a distribution that was almost normal in both sets of patients. On average, we had 
measurements of at least 3 samples per patient, corresponding to different follow-up visits, in order to minimize 
the intra-assay variability. Nevertheless, we had previously reported that VIP serum levels do not vary relevantly 
during the follow-up22. However, several variables may contribute to slight modifications in VIP levels as well as 
they can interact with the effect of variants of VIP gene on these levels, so we performed several multivariate anal-
yses based on generalized estimating equations nested by patient and visit using the xtgee command of Stata 12 
for Windows (Stata Corp LP, College Station, Texas, USA). This model allows us to achieve a better adjusted VIP 
value for each patient. First, we performed the multivariate models by adding all variables with a p value <0.15 
in the bivariate analysis. Then, we used the manual backward-stepwise selection to fit the final models by sequen-
tially removing variables with p > 0.15. Multivariable models were in all cases adjusted by the variable “assay 
plate” in order to minimize the inter-assay variability. Since the intensity of treatment is a variable calculated at a 
specific point of follow-up (after two years), the adjustment of the multivariate model for its study was performed 
by means of generalized linear models using the Stata glm command.
Data availability. All relevant data are within the paper and its Supporting Information files. The datasets 
generated and/or analysed during the current study are not publicly available due to the confidential nature of the 
clinical data but are available from the corresponding author on reasonable request.
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